| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Participant Protection Policy FAQ
- Talking Glossary of Genetic Terms
Method: Enzyme-linked Immunosorbent Assay (EIA) (R&D kit # HSTA00C)
Technical Aspects:
Vendor R & D Systems, Minneapolis, MN Units pg/mL Minimum Detectable Level 0.06 - 0.32 pg/mL FHS Specimen Characteristics:
- a. Plasma
- b. Frozen samples -80°C
- Study Weblinks:
- Study Design:
- Prospective Longitudinal Cohort
- Study Type:
- Longitudinal
- Total number of consented subjects: 2516
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Study History
Offspring Exam 7 (2537 participants)
The Original cohort began Exam 1 in 1948 (9/1948 - 4/1953) and has continued with biennial examinations to the present. Exam 29 was performed from 4/2006 - 12/2007.
The Offspring cohort began Exam 1 in 1971 (8/1971 - 9/1975) and has on average been examined every 3 to 4 years since enrollment. However, there was an eight year window between Exam 1 and Exam 2. Exam 8 was performed from 3/2005 - 1/25/2008.
The Generation 3 cohort Exam 1 was performed 4/2002 - 7/2005.
Examination of all three cohorts is ongoing.
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Cardiovascular System
- Authorized Data Access Requests
- Study Attribution
-
-
Principal Investigator
- James Meigs, MD, MPH. Massachusetts General Hospital, Boston, MA, USA.
-
Institutions
- The National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
-
Principal Investigator